Gabapentin

Gabapentin is used to treat bipolar disorder, partial epilepsies, postherpetic neuralgia and phobic disorders, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Dec 30, 1993, and the first generic was approved Sep 12, 2003. FDA's Orange Book lists 107 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $579 million on Gabapentin across 36.8 million claims for 8.0 million beneficiaries.

Gabapentin is available as 292 NDCs from 40 manufacturers (276 generic, 16 brand), with NADAC prices from $0.02 to $16.98 per EA — the most expensive product costs about 810× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.